Entrada Reports Phase 1/2 DMD Cohort 1 Data

Entrada reported favorable safety and tolerability for ENTR-601-45 at 5 mg/kg, with a 0.10% mean dystrophin increase from baseline. Enrollment in Cohort 2 at 10 mg/kg is complete, with data expected in H1 2027.